This patent application is a U.S. national phase entry of international application no. PCT/IB2018/001417 filed Nov. 16, 2018; claims the benefit of GB1719014.1 filed Nov. 16, 2017; and GB1719027.3 filed Nov. 16, 2017; each of which is incorporated herein by reference in their entirety.
Exudating wounds may be treated by providing negative pressure to the space above the wound to promote healing in a process often referred to as negative pressure wound therapy (NPWT). During NPWT, effluent such as exudate is removed from the wound and collected. In some therapies, the effluent is stored in a fluid collection apparatus positioned between the source of negative pressure and a the wound site. Typically the apparatus has a specific orientation to prevent exudate drawn into the apparatus from reaching the air outlet of the collection apparatus or otherwise prevent excess exudate from being drawn into the collection apparatus and/or fluid or other undesirable material being drawn into the negative pressure supply. As a consequence of this specific orientation, the patient may be restricted in mobility. In addition, care must be taken so that the specific orientation is not disrupted, which can interrupt the NPWT process.
In one aspect, disclosed herein is an apparatus configured to allow for orientation independence during negative pressure wound therapy (NPWT). For instance, an apparatus comprising multiple sides (e.g., six sides), may be positioned in such a way that any of the multiple sides may be laid against a horizontal or substantially horizontal surface in use. As a non-limiting example, the apparatus may be capable of operating upside down such as may occur if carried in a bag when mobile or otherwise supported or placed in that orientation. The apparatus may additionally or alternatively be hung to a drip stand or other suitable device or affixed to a wall by an attachment point located on any of the multiple sides. This orientation independence may be achieved, for example, by arranging a first impeding element at a first end of a first fluid pathway defined by a first fluid defining element, such as a chamber or tube, in fluid communication with a source of negative pressure, and a second impeding element at a second end of the first fluid pathway, such that during NPWT, air may be preferentially drawn through the impeding element and into the first fluid pathway while liquid flow is impeded. Preferably, the first end of the first fluid defining element and a first side of the apparatus are in substantially fluid tight communication. Preferably, the second side of the apparatus opposes the first side of the apparatus. In an exemplary embodiment, as the apparatus fills with liquid, liquid may be drawn through the impeding elements and into the fluid pathway. As a non-limiting example, the liquid is drawn through the impeding elements and into the fluid pathway when the apparatus reaches a full or nearly-full state. To hinder liquid from being drawn from the fluid pathway into the source of negative pressure, the fluid pathway may comprise an air permeable member positioned within the fluid pathway to separate liquid drawn into the fluid pathway from the source of negative pressure. In some embodiments, the air permeable member is a filter that impedes liquid and solid material from passing through the member. In some instances, liquid drawn into the fluid pathway may saturate the air permeable member or the air permeable member may reach a predefined saturation level, which may cause an undesired change to the intended negative pressure level. In some cases, this pressure change may be used to detect or sense that the apparatus may be in a full or nearly-full state, and cause generation of negative pressure to halt. Accordingly, liquid may be prevented from entering into the source of negative pressure through the chamber once the air permeable member is saturated or reaches a pre-defined saturation level. In other instances, undesirable material such as wound tissue or absorbent material within the apparatus may block or clog the air permeable member which may cause an undesired change to the intended negative pressure level. In some cases, this pressure change may be used to detect or sense that the apparatus may not be functioning properly, and cause generation of negative pressure to halt. In some cases, this negative pressure change may be due to both of the aforesaid conditions. In some instances, the apparatus comprises an optional aromatic cartridge that may prevent external release of noxious odors drawn into the apparatus. The apparatus may further include one or more optional supports, such as a web or anchor to further retain the impeding element or elements in the chamber.
In some embodiments, disclosed herein are devices for negative pressure wound therapy comprising a collection vessel, a first fluid defining member configured to be in fluid communication with a source of negative pressure, a first impeding element positioned at a first end of the first fluid defining member, a second impeding element positioned at a second end of the first fluid defining member, and a second fluid defining member defining a pathway for dispensing fluid drawn from a wound site of a patient during negative pressure wound therapy into a collection region of the collection vessel; and wherein the first impeding element impedes fluid dispensed within the collection region from entering a first end of the first fluid defining member and the source of negative pressure, and the second impeding element impedes fluid dispensed within the collection region from entering a second end of the first fluid defining member and the source of negative pressure.
In some embodiments, the first and/or second impeding element of the devices disclosed herein comprise foam, in some instances open cell foam, and in further instances the impeding elements comprise polyurethane, polyether, polyvinyl alcohol (PVA), or a combination thereof. In some embodiments, the foam is a reticulated polyurethane foam. In some embodiments, the first fluid defining member is configured to hold the first and the second impeding elements in place within the fluid collection apparatus. In some embodiments, the first fluid defining member has a circular cross-section and/or may comprise a polycarbonate material. In yet other embodiments, the inner diameter of the first fluid defining member is between about 13 and about 23 mm, and the outer diameter of the first fluid defining member is between about 17 mm and about 27 mm.
In yet other embodiments, the devices disclosed herein further comprises a filter positioned within the first fluid defining member. In some embodiments, the filter is a hydrophobic filter; alternatively the filter comprises a pore size of between about 0.2 micron to about 0.8 micron. In other embodiments, the filter comprises polyethersulfone (PES), polytetrafluorethylene (PTFE), cellulose acetate, or a cellulose nitrate membrane.
In yet other embodiments, the devices disclosed herein further comprises a carbon filter. In yet other embodiments, the carbon filter comprises from about 25 g/m2 to about 200 g/m2 of activated carbon.
In some embodiments, the second fluid defining member comprises an elastomer, plastic, polyvinyl chloride (PVC), silicone, ethylene propylene diene monomer (EPDM), Viton, or a combination thereof. In some embodiments, the devices disclosed herein further comprises an absorbent material; in other embodiments, the absorbent material comprises a superabsorbent material, a fibrous structure impregnated with the superabsorbent material, sodium polyacrylate and cellulose pulp in the form of a sheet material, or combinations thereof. In other embodiments, the absorbent material comprises one or more layers of absorbent material within the fluid collection apparatus. In other embodiments, the absorbent material is provided within a sachet. In yet other embodiments, the sachet is dissolvable. In yet other embodiments, the devices disclosed herein further comprises a first wicking layer. In still other embodiments, the first wicking layer is positioned between the first impeding element and the absorbent material. In still other embodiments, the second fluid defining member extends through the first impeding element and comprises an outlet end positioned adjacent to the first wicking layer to wick the dispensed fluid into the absorbent material. In yet other embodiments, the outlet end of the second fluid defining member is positioned within about 10-60 mm of the first wicking layer. In yet other embodiments, the devices disclosed herein further comprises a second wicking layer. In still other embodiments, the second wicking layer is positioned between the absorbent material and the second impeding element. In yet other embodiments, the devices disclosed herein are configured to hold up to about 900 ml of fluid, up to about 600 ml of fluid or up to 300 ml of fluid. In still other embodiments, the devices disclosed herein further comprises an extension element extending the second fluid defining member to an area adjacent to or within the collection region of the collection vessel. In still other embodiments, the devices disclosed herein further comprise a cover. In still other embodiments, the first impeding element and the second impeding element are configured such that when the collection region of the collection vessel is filled with liquid to at least about 25% capacity by volume and sealed, in all orientations of the apparatus at least one of the first and second ends of the first fluid defining member is not submerged in liquid. In still other embodiments, the first impeding element and the second impeding element are configured such that when the collection region of the collection vessel is filled with fluid to at least about 50% capacity by volume and sealed, in all orientations of the apparatus at least one of the first and second ends of the first fluid defining member is not submerged in liquid. In some cases, the liquid is water. In some cases, the liquid is a physiological saline solution. As a non-limiting example, the physiological saline solution is defined in EN13726-1 as Test solution A.
Also included herein are methods for performing negative pressure wound therapy with the fluid collection apparatus devices disclosed herein. In some embodiments, the fluid collection apparatus devices disclosed herein comprises six sides, and the fluid collection apparatus in use is configured to be: (a) positioned with any of the six sides against a horizontal surface, and/or (b) hung from an attachment point on any of the six sides.
Also disclosed herein are methods of collecting fluid from a wound site of a subject, the method comprising: a) providing: i) a wound dressing positioned over the wound site, ii) a source of negative pressure, and iii) a fluid collection apparatus comprising a first fluid defining member in fluid communication with the source of negative pressure, a first impeding element positioned at a first end of the first fluid defining member, a second impeding element positioned at a second end of the first fluid defining member, and a second fluid defining member in fluid communication with the wound dressing; wherein the second fluid defining member defines a pathway for dispensing fluid drawn from the wound site into a fluid collection region of the fluid collection apparatus; and b) applying a negative pressure from the source of negative pressure to the wound site via the fluid collection apparatus to draw fluid from the wound site, through the second fluid defining member, and into the fluid collection region of the fluid collection apparatus; wherein the fluid comprises liquid and air, and fluid is retained in the fluid collection region and air is drawn through the first impeding element and/or the second impeding element, into the interior of first fluid defining member, and towards the source of negative pressure.
In some embodiments, the the fluid collection apparatus of the methods disclosed herein comprises multiple sides, and the fluid collection apparatus in use is: (a) positionable with any of the sides against a horizontal surface and/or (b) hung from an attachment point on any of the sides. In some embodiments, the fluid collection apparatus is suspended from one or more attachment points on the fluid collection apparatus. In some embodiments, when the fluid collection region is full or nearly full of fluid and/or other material than air, and the fluid saturates the filter or the filter reaches a pre-defined saturation level, a pressure drop is generated or sensed to stop application of negative pressure. In some embodiments, up to about 900 ml of fluid, up to about 600 ml of fluid, or up to about 300 ml of fluid is retained in the fluid collection region.
Also disclosed herein are multi-orientation fluid collection apparatus devices for negative pressure wound therapy comprising: a) a collection vessel comprising a first side and a second opposing side, b) optionally, a cover connected to the first side of the collection vessel, c) a first fluid pathway in fluid communication with a source of negative pressure, the first fluid pathway positioned between: (i) a first impeding element positioned at an interior of the cover or interior of the first side of the collection vessel and a (ii) second impeding element positioned at an interior of the second side of the collection vessel, wherein the first impeding element and the cover or first side of the collection vessel are in substantially fluid tight communication, d) a filter positioned within the first fluid pathway and between the first impeding element and the second impeding element, and e) a second fluid pathway for introducing exudate into the collection vessel.
In some embodiments, the collection vessel of the devices disclosed herein comprises additional sides positioned between the first and second opposing sides, and the multi-orientation fluid collection apparatus in use is capable of being: (a) positioned with the first side, the second opposing side, or any of the additional sides against a horizontal surface, and/or (b) hung from an attachment point on the first side, the second opposing side, or any of the additional sides.
Also disclosed herein are multi-orientation fluid collection apparatus devices connected to a source of negative pressure for collecting wound exudate, the apparatus comprising a collection vessel; a first fluid pathway comprising a first and a second end with impeding elements at the first and second ends, said first fluid pathway and a first side of the apparatus in fluid tight or substantially fluid tight communication with the source of negative pressure; and a second fluid pathway for drawing fluid from a wound site into the apparatus. In some embodiments, in use said second fluid pathway and said wound site are in fluid tight or substantially fluid tight communication. In some embodiments, the devices comprise an air permeable member situated within the first fluid pathway. In some embodiments, the devices comprise a third fluid pathway situated within the first fluid pathway and in fluid communication with the air permeable member for receiving air from the air permeable member; said third fluid pathway within said first fluid pathway and a first side of the apparatus in fluid tight or substantially fluid tight communication and the third fluid pathway in fluid communication with the source of negative pressure. In some embodiments, the first fluid pathway is defined by a first fluid defining member. In some embodiments, the first fluid defining member is a chamber. In some embodiments, the second fluid defining member is a fluid inlet for receiving fluid from the wound site under negative pressure. In some embodiments, the air permeable member comprises one or more filters. In some embodiments, the filter comprises a hydrophobic filter. In some embodiments, the impeding elements comprise foam.
In one aspect, provided herein are fluid collection apparatuses for collecting fluid from a patient during negative pressure wound therapy (NPWT). A first exemplary embodiment 100 of a fluid collection apparatus is shown in a front side view in
Apparatus 100 houses chamber 122 and collection region 123 within an interior region formed by a cover 110 and collection vessel 111. Cover 110 comprises a first opening 124 configured to connect the apparatus to a source of negative pressure and to provide a first pathway in fluid communication between the chamber of the apparatus and the source of negative pressure. Cover 110 further comprises a second opening 125 configured to connect the apparatus to a wound dressing and to provide a second pathway in fluid communication between the wound site and the apparatus. As shown in
In an exemplary embodiment, air is preferentially drawn into the chamber 122 from the collection region 123 through a first impeding element 103 positioned at the top of the apparatus or a second impeding element 103 positioned at the bottom of the apparatus. Impeding elements 103 are shown in
In some embodiments, the first and/or second impeding elements are configured to prevent the passage of particulates of about 100 microns to about 850 microns in size, e.g., about 400 microns in size. For a porous impeding element, the impeding element may comprise a tortuous path that hinders particulates smaller than the pore size from passing through the impeding element.
The impeding element may comprise an open-cell foam. In some cases, the foam comprises polyurethane, polyether, polyvinyl alcohol (PVA), or a combination thereof. For example, the impeding element comprises polyurethane foam. In some cases, the open-cell is compressed within the apparatus by the chamber tube 102, as described above. In some embodiments, the impeding element comprises a polypropylene, polyester, or rayon felt filter media such as supplied by Superior Felt and Filtration. In some cases, the impeding element comprises a polypropylene filter material, such as supplied by Pall Inc. In some embodiments, the impeding element comprises a fibrous material, for example, a polyester material. In some embodiments, the impeding element comprises a nonwoven material. Additional exemplary impeding elements are envisioned that comprise multiple small holes or capillaries through which air may preferentially pass during NPWT over liquid and/or particulate materials.
In some embodiments, the apparatus comprises an impeding element that is not positioned at either end of a chamber tube 102. As a non-limiting example, the impeding element is a series of small holes in a rigid structure e.g., radially holes or castellation slots through the wall of chamber tube 102 that may provide a fluid pathway that would provide resistance to liquid and preferential movement to air. In some such embodiments, chamber tube 102 may seal to the inside surface of the cover 110 and collection vessel 111. In some cases, the holes or slots are small enough to provide the appropriate flow resistance to liquid.
During NPWT, fluid is drawn into the collection region 123 through the pathway defining member 115 and optional fluid extension tube 107. Second fluid defining member 115 may extend to a desired length without the need for fluid extension tube 107, or may be connected to fluid extension tube 107 to establish an overall desired length of the two elements together. In a preferred embodiment, second fluid defining member 115 (with our without fluid extension tube 107) extends to a central region of collection region 123 to direct exudate and air to the central region. In some embodiments, the second fluid defining member 115 extends through the first impeding element. In other embodiments, the second fluid defining member 115 does not extend through the first impeding element. As a non-limiting example, the first impeding member may be formed such that wound fluid may pass into the collection region 123 without passing through the first impeding element. Collection region 123 may include an absorbent region comprising an absorbent material. Such absorbent material may be arranged as layers of absorbent material 105, and optionally wicking layers 104. If present, the wicking layers 104 are configured to transport liquid via capillary action through the wicking layers and into the layers of absorbent material to distribute fluid throughout the collection region 123. In some cases, the first and second impeding elements prevent the absorbent material from entering chamber 122.
Apparatus 100 further comprises a filter assembly 101, which is shown in an exemplary embodiment in
During NPWT, a negative pressure source and wound dressing are connected to the apparatus such that fluid (including air and liquid exudate) is drawn from the wound into the apparatus by exerted negative pressure. Wound fluid enters the collection region 123 through opening 125, passing through second fluid defining member 115 and optional extension tube 107, following a path as generally depicted by the hashed arrows in
A second embodiment 200 of a fluid collection apparatus is shown from a front side in
A third embodiment of a fluid collection apparatus is shown in
In still other embodiments, the collection region 123 comprises an absorbent material, for example, superabsorbent material, such as superabsorbent granules, particles or other material capable of absorbing large amounts of liquid exudate relative to its own mass. Examples of superabsorbent polymers include, but are not limited to, cellulose or cellulose-derivative, for example, carboxymethyl cellulose, polyacrylate, including sodium polyacrylate, polyacrylamide and polyacrylamide co-polymers, ethylene maleic anhydride copolymers, crosslinked-carboxymethylcellulose, polyvinyl alcohol copolymers, cross-linked polyethylene oxide, polyacrylonitrile copolymers and combinations thereof. Absorbent material, for example superabsorbent polymers, may optionally include materials capable of absorbing odors or other noxious elements present in exudate and/or other excipients needed to, for example, increase particle size or surface area. In some cases, an odour absorbing material, such as activated carbon particles, may be included or added into to an impeding element, and/or wicking layer to provide an additional means to control odour such that air passing through the apparatus passes over odour absorbing material such as activated carbon.
A fourth embodiment of a fluid collection apparatus is shown in
A fifth embodiment of a fluid collection apparatus is shown in
Each of the apparatuses shown may comprise attachment points 118 for hanging each apparatus in storage and/or during NPWT from one or more of its sides. The sides of apparatus 100 are depicted in
The apparatus and features thereof shown in
As used herein, a fluid is inclusive of a liquid and/or gas. As a non-limiting example, fluid drawn into an apparatus during a negative pressure therapy may comprise a mixture of liquid and gas, and the liquid may be retained within a collection region of the apparatus. In some cases, a fluid comprising a mixture of liquid and gas may be retained within the collection region. In some cases, the collection region comprises an absorbent material configured to absorb and retain liquid from a fluid drawn into the collection region, where the fluid drawn into the collection region comprises the liquid or a mixture of the liquid and a gas. In further cases, at least some of a gas drawn into the collection region may be retained within that region. In other cases, while there may be no net increase of gas in the collection region during a negative pressure therapy, there may instead be a net decrease of gas in the collection region during negative pressure therapy.
Fluid Collection Apparatus
In one aspect, a fluid collection apparatus comprises a cover, a collection vessel, a chamber tube configured to be in fluid communication with a source of negative pressure, a first impeding element positioned at a first end of a first tube, a second impeding element positioned at a second end of the first tube, and a fluid inlet tube extending through the first impeding element. In some embodiments, the fluid inlet tube optionally comprises an extension such that the outlet end dispenses fluid drawn from a wound site of a patient during NPWT into a collection region of the collection vessel. In some instances, the first impeding element impedes fluid dispensed within the collection region from entering the first end of the first tube and the source of negative pressure. In some instances, the second impeding element impedes fluid dispensed within the collection region from entering the second end of the first tube and the source of negative pressure. The chamber tube may, for example, be configured to hold the first and the second impeding elements in place within the fluid collection apparatus. In some embodiments, the first and/or second impeding elements may comprise a material that allows air to flow freely within the material, while absorbing liquid exudate and/or restricting entry or movement of larger particles. In some embodiments, the impending element comprises foam, preferably an open cell foam. Exemplary foams include polyurethane, polyether, and polyvinyl alcohol (PVA). In some cases, the polyurethane foam is a reticulated polyurethane foam.
In one aspect, a fluid collection apparatus comprises a cover, a collection vessel, and an interior region comprising a chamber tube, a first impeding element positioned at a first end of the tube, a second impeding element positioned at a second end of the tube, and an absorbent material. In some instances, the absorbent material may be positioned external to the tube. In some embodiments, the first and second impeding elements may inhibit or prevent transfer of the absorbent material to the interior of the tube. In some embodiments, the first and/or second impeding elements may comprise foam; in other embodiments, the first and/or second impeding elements may comprise an open cell foam. Exemplary foams include polyurethane, polyether, and polyvinyl alcohol (PVA). In some cases, the polyurethane foam is a reticulated polyurethane foam.
In another aspect, a fluid collection apparatus comprises a cover, a collection vessel, a chamber tube, a first impeding element positioned at a first end of the tube, a second impeding element positioned at a second end of the tube, and a collection region external to the tube. In some embodiments, the first impeding element provides a first air path from the collection region to the interior of the tube, and the second impeding element provides a second air path from the collection region to the interior of the tube. In some embodiments, the first and/or second impeding elements may comprise foam; in other embodiments, the first and/or second impeding elements may comprise open cell foam. Exemplary foams include polyurethane, polyether, and polyvinyl alcohol (PVA). In some cases, the polyurethane foam is a reticulated polyurethane foam.
In another aspect, a fluid collection apparatus comprises a cover, a collection vessel, a fluid inlet tube, a fluid collection region, and at least one impeding element; wherein the fluid inlet tube optionally comprises an extension of an outlet end for dispensing fluid collected during negative pressure wound therapy into a fluid collection region of the collection vessel/In some embodiments, the fluid inlet tube extends through the impeding element such that the outlet end of the tube is positioned within the fluid collection region, and the outlet end of the tube is positioned adjacent to the absorbent region. In some instance, an optional extension may be provided to extend the outlet end of the fluid inlet tube such that the outlet end in larger apparatus configurations may be positioned adjacent to the absorbent region. In some embodiments, the first and/or second impeding elements may comprise foam; in other embodiments, the first and/or second impeding elements may comprise open cell foam. Exemplary foams include polyurethane, polyether, and polyvinyl alcohol (PVA). In some cases, the polyurethane foam is a reticulated polyurethane foam.
In one aspect, a fluid collection apparatus comprises a collection vessel, a fluid inlet tube, a fluid collection region, and at least one impeding element. In some instances, the fluid inlet tube optionally comprises an extension such that the outlet end of the fluid inlet tube is capable of dispensing fluid collected during negative pressure wound therapy into a fluid collection region of the collection vessel such that the outlet end of the fluid inlet tube may be positioned adjacent to or within the fluid collection region. In some instances, the outlet end of the fluid inlet tube may be positioned adjacent to an optional absorbent region. In yet other embodiments, the outlet end of the fluid inlet tube may be positioned within a region comprising, for example, superabsorbent material. In some instances, the superabsorbent may be contained within a bag, pouch or container, for example a sachet. In other instances, the bag, pouch or container may be dissolvable, for example, a dissolvable sachet. In some embodiments, the first and/or second impeding elements may comprise foam; in other embodiments, the first and/or second impeding elements may comprise open cell foam. Exemplary foams include polyurethane, polyether, and polyvinyl alcohol (PVA). In some cases, the polyurethane foam is a reticulated polyurethane foam.
In one aspect, a fluid collection apparatus comprises a collection vessel, a chamber tube configured to be in fluid communication with a source of negative pressure, a first impeding element positioned at a first end of a first tube, a second impeding element positioned at a second end of the first tube, and a fluid inlet tube extending through the first impeding element. In some embodiments, the fluid inlet tube optionally comprises an extension such that the outlet end dispenses fluid drawn from a wound site of a patient during NPWT into a collection region of the collection vessel. In some instances, the first impeding element impedes fluid dispensed within the collection region from entering the first end of the first tube and the source of negative pressure. In some instances, the second impeding element impedes fluid dispensed within the collection region from entering the second end of the first tube and the source of negative pressure. The chamber tube may, for example, be configured to hold the first and the second impeding elements in place within the fluid collection apparatus. In some embodiments, the first and/or second impeding elements may comprise a material that allows air to flow freely within the material, while absorbing liquid exudate and/or restricting entry or movement of larger particles. In some embodiments, the impending element comprises foam, preferably an open cell foam. Exemplary foams include polyurethane, polyether, and polyvinyl alcohol (PVA). In some cases, the polyurethane foam is a reticulated polyurethane foam. In some cases, the apparatus further comprises a cover configured to connect to the collection vessel.
In one aspect, a fluid collection apparatus comprises a collection vessel, and an interior region comprising a chamber tube, a first impeding element positioned at a first end of the tube, a second impeding element positioned at a second end of the tube, and an absorbent material. In some instances, the absorbent material may be positioned external to the tube. In some embodiments, the first and second impeding elements may inhibit or prevent transfer of the absorbent material to the interior of the tube. In some embodiments, the first and/or second impeding elements may comprise foam; in other embodiments, the first and/or second impeding elements may comprise an open cell foam. Exemplary foams include polyurethane, polyether, and polyvinyl alcohol (PVA). In some cases, the polyurethane foam is a reticulated polyurethane foam. In some cases, the apparatus further comprises a cover configured to connect to the collection vessel.
In another aspect, a fluid collection apparatus comprises a collection vessel, a chamber tube, a first impeding element positioned at a first end of the tube, a second impeding element positioned at a second end of the tube, and a collection region external to the tube. In some embodiments, the first impeding element provides a first air path from the collection region to the interior of the tube, and the second impeding element provides a second air path from the collection region to the interior of the tube. In some embodiments, the first and/or second impeding elements may comprise foam; in other embodiments, the first and/or second impeding elements may comprise open cell foam. Exemplary foams include polyurethane, polyether, and polyvinyl alcohol (PVA). In some cases, the polyurethane foam is a reticulated polyurethane foam. In some cases, the apparatus further comprises a cover configured to connect to the collection vessel.
In another aspect, a fluid collection apparatus comprises a collection vessel, a fluid inlet tube, a fluid collection region, and at least one impeding element; wherein the fluid inlet tube optionally comprises an extension of an outlet end for dispensing fluid collected during negative pressure wound therapy into a fluid collection region of the collection vessel/In some embodiments, the fluid inlet tube extends through the impeding element such that the outlet end of the tube is positioned within the fluid collection region, and the outlet end of the tube is positioned adjacent to the absorbent region. In some instance, an optional extension may be provided to extend the outlet end of the fluid inlet tube such that the outlet end in larger apparatus configurations may be positioned adjacent to the absorbent region. In some embodiments, the first and/or second impeding elements may comprise foam; in other embodiments, the first and/or second impeding elements may comprise open cell foam. Exemplary foams include polyurethane, polyether, and polyvinyl alcohol (PVA). In some cases, the foam is a reticulated polyurethane foam. In some cases, the apparatus further comprises a cover configured to connect to the collection vessel.
In another aspect, a fluid collection apparatus comprises a collection vessel; optionally, a cover connected to a first side of the collection vessel; a first fluid pathway in fluid communication with a source of negative pressure, the first fluid pathway positioned between: (i) a first impeding element positioned at an interior of the cover or interior of the first side of the collection vessel and a (ii) second impeding element positioned at an interior of a second side of the collection vessel opposing the first side, wherein the first impeding element and the cover or first side of the collection vessel are in substantially fluid tight communication; a filter positioned within the first fluid defining member and between the first impeding element and the second impeding element; and a second fluid pathway for introducing exudate into the collection vessel. In some embodiments, the first and second impeding elements serve as, for example, a pre-filter to inhibit liquid from reaching the filter positioned within the first fluid defining member. In some embodiments, the first and the second impeding elements are not hydrophobic filters. In some embodiments, the filter and the impeding elements do not comprise the same material. In some embodiments, the first and the second impeding elements preferentially allow passage of air to enter into the first fluid defining member, but as the collection vessel fills, some liquid may pass into the first fluid defining member. When sufficient liquid has entered into the first fluid defining member and covers the filter, a signal may be received indicating that the collection vessel could be full or at least about 50% full.
In some embodiments, any fluid collection apparatus described herein comprising an air permeable filter positioned within the chamber. In some cases, the air permeable filter comprises a hydrophobic filter. The air permeable filter may have a pore size of about 0.2 microns to 0.8 microns, or about 0.2 microns, 0.45 microns, or 0.8 microns. The air permeable filter may comprise polyethersulfone (PES), polytetrafluorethylene (PTFE) (e.g., as manufactured by Dow Corning), cellulose acetate, cellulose nitrate membranes, or a combination thereof. In some embodiments, the apparatus further comprises a carbon filter.
In some embodiments, any fluid collection apparatus described herein may comprise an absorbent material. The absorbent material may comprise a superabsorbent material. For example, the absorbent material may comprise a fibrous structure impregnated with the superabsorbent material. The superabsorbent material may, for example, also comprise cellulose or a cellulose-derivative. In some cases, the absorbent material comprises one or more layers of absorbent material. In some cases, the absorbent material may be provided within a sachet. The absorbent material may also be adjacent to a wicking layer.
In some embodiments any fluid collection apparatus described herein comprises six sides, and the fluid collection apparatus in use is configured to be: (a) positioned with any of the six sides against a horizontal surface, and/or (b) hung from an attachment point on any of the six sides.
Fluid Collection Apparatus Components
In some embodiments, a fluid collection apparatus comprises a collection vessel and a cover. In some embodiments, the collection vessel may not include a separate cover but instead form all sides or walls of the vessel itself. The collection vessel may comprise a rigid plastic, e.g., a gamma sterilisable polycarbonate. An exemplary polycarbonate is Makrolon 2458. The cover may also comprise a rigid plastic such as a gamma sterilisable polycarbonate. Exemplary polycarbonates are Makrolon 2458 and RAL 9016. The cover may also comprise an O-ring for connecting the apparatus to a source of negative pressure and/or wound dressing. The O-ring may comprise nitrile, silicone, ethylene propylene diene monomer (EPDM), Viton, or a combination thereof. In some cases, the O-ring is black EPDM 70 Shore A.
The collection vessel may be configured to hold from about 100 ml to about 1200 ml of liquid in a collection region, e.g., a region comprising an absorbing material. In some cases, the collection vessel may hold about 100 ml, about 200 ml, about 300 ml, about 400 ml, about 500 ml, about 600 ml, about 700 ml, about 800 ml, about 900 ml, about 1000 ml, about 1100 ml, and about 1200 ml. In some embodiments, apparatus 100 is configured to hold about 600 ml of liquid. In some embodiments, apparatus 100 is configured to hold about 900 ml of liquid. In some embodiments, apparatus 200 is configured to hold about 600 ml of liquid. In some embodiments, apparatus 200 is configured to hold about 900 ml of liquid. In some embodiments, apparatus 300 is configured to hold about 300 ml of liquid.
In some embodiments, the first and second impeding elements of the apparatus comprise foam. The foam may be in the form of a layer that provides an air path from the collection region of the canister to the chamber and on to the negative pressure source. The foam may also prevent transfer of absorbing material to the filter assembly. In some cases, the foam is an open cell foam. In some cases, foam comprises polyurethane, polyether, polyvinyl alcohol (PVA), or a combination thereof. In an exemplary embodiment, the foam comprises polyurethane, e.g., a reticulated polyurethane foam. An exemplary reticulated polyurethane foam is Blue RAL 5017.
In some embodiments, a fluid collection apparatus comprises an absorbent region comprising an absorbent material. In some cases, the absorbent material comprises one or more layers of absorbent material. In some cases, the absorbent material has about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 layers of absorbent material. As an exemplary embodiment, the absorbent material has 6 layers of absorbent material. In some cases, the absorbent material is provided within a sachet. The sachet may be dissolvable.
In some aspects, an absorbent material comprises a super absorbent material. Non-limiting examples of super absorbent materials include a material or combination of materials that absorb about or at least about 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 120-, 140-, 160-, 180-, 200-, 250-, 300-, 400-, or 500-times the super absorbent material's weight in water. In some cases, a super absorbent material absorbs about 20-500 times its weight in water, or absorbs about 50-500 times its weight in water. When the super absorbent is used in a bag or sachet for retaining biological fluids having salinity such as exudates, the super absorbent fluid may absorb between about 4 and about 10 times its weight in a saline liquid.
In some aspects, an absorbent material expands from a first thickness to a second thickness upon absorption of fluid, wherein the second thickness is less than or equal to the maximum thickness of the absorbent material. In some embodiments, the first thickness refers to the thickness of the absorbent material prior to absorption of fluid during a negative pressure therapy. For example, the first thickness is the thickness of the expandable absorbent material supplied and/or stored with a fluid collection apparatus for use in negative pressure therapy. In some embodiments, the absorbent material is a super absorbent material that expands during absorption of fluid. In some cases, the first thickness of the expandable absorbent material is between about 3 mm and 15 mm, or between about 5 mm and 10 mm. In some cases, the maximum thickness is between about 15 mm and 50 mm, or between about 20 mm and 35 mm. In some cases, the maximum thickness of the expandable absorbent material is about 1.2-, 1.4-, 1.6-, 1.8-, 2-, 2.5-, 3-, 3.5-, 4-, 4.5- or 5-times the first thickness. In some cases, the maximum thickness of the expandable absorbent material is about 1.5-5, 1.5-4, 1.5-3, 1.5-2.5, or 1.5-2 times the first thickness.
Non-limiting examples of absorbent materials include polyacrylate, non-woven material, cellulose fibres, tissue paper, polyacrylamide copolymer, and combinations thereof. A non-woven material includes a polyester staple fibre. In a non-limiting example, an apparatus comprises the superabsorbent polymer polyacrylate. As another non-limiting example, an apparatus comprises the superabsorbent polymer Needlefelt type 0570N700400 (Technical Absorbents). In some cases, an apparatus comprises two or more materials with absorbing properties. In some cases, an apparatus comprises a mixture of super absorbent polymer and cellulose fibers. In some embodiments, an absorbent material comprises a base fibrous structure impregnated with super absorbing polymer particles. For example, Specificall cellulose Absorbent Pad 113.
In some embodiments, an absorbent material is in a powder or granular form within a bag or sachet. In some embodiments, the absorbent material is enclosed within a casing within the apparatus. In some embodiments, the absorbent material comprises a superabsorbent polymer. The casing is sometimes referred to as a transmissive material or layer which allows fluid to flow into the casing to the absorbent material, while retaining the absorbent material within the casing. In some cases, the transmissive material has a wicking property, where fluid transfer into the casing is facilitated by the wicking property of the transmissive material, for example, via capillary action. In other or additional cases, a separate and/or additional wicking layer is provided on an exterior of the casing to draw liquid into the casing to the absorbing material. In some cases, a layer of the transmissive material enclosing the absorbent material is between about 0.02 mm and 0.2 mm thick or between about 0.08 mm and 0.15 mm thick. Non-limiting examples of transmissive materials include non-woven polypropylene, cellulose fibres, non-woven HDPE and a combination thereof.
In some embodiments, an absorbent material is provided in the collection region of the apparatus as loose particles, e.g., superabsorbent particles that are not contained in a bag or casing and are not formed as layers.
In some aspects of the disclosure, a fluid collection apparatus comprises a wicking material. Wicking materials include materials configured to receive liquid and then rapidly transport the liquid, for example, via capillary action, to another material adjacent the wicking material. For instance, the wicking material receives liquid drawn into the collection region of the apparatus and then transfers the liquid to the absorbent material, where the absorbent material absorbs and retains the liquid. In some embodiments, a wicking material wicks more than 15 mm of water vertically over a time period of 24 hours. In some cases, the absorbent material is a superabsorbent polymer. In exemplary embodiments, the apparatus comprises a wicking material positioned adjacent an absorbent material described herein. Non-limiting examples of wicking materials include cellulose pulp, cotton, tissue paper, non-woven polyester, and a combination thereof. In some configurations, about a 0.05-10 mm, or about a 0.2-2 mm layer of wicking material is positioned adjacent to an absorbent material.
For an apparatus comprising an absorbent region comprising an absorbent material and optionally a wicking material, the distance between the fluid inlet tube or extension tube and the absorbent region may be from about 10 mm to about 60 mm. As a non-limiting example, for an apparatus configured to hold about 300 ml of liquid, the distance is about 15 mm. As another example, for an apparatus configured to hold about 600 ml of liquid, the distance is about 30 mm. As a further example, for an apparatus configured to hold about 900 ml of liquid, the distance is about 40 mm.
The first fluid defining member, or chamber tube, that provides space for the filter assembly may be rigid. This member may be cut from an extruded tube or moulded to suit a particular apparatus. As a non-limiting example, a first fluid defining member comprises clear polycarbonate, such as Makrolon 2458. In some embodiments, the first fluid defining member has a circular, square, rectangular, or other cross section. For an apparatus comprising a circular cross section, the filter assembly may be positioned within the chamber such that the face of the filter is held away from a wall to allow for free passage of air. In some cases, the inner diameter of the chamber tube is from about 10 mm to about 24 mm, from about 12 mm to about 24 mm, from about 14 mm to about 24 mm, from about 16 mm to about 24 mm, from about 18 mm to about 24 mm, from about 12 mm to about 22 mm, from about 12 mm to about 20 mm, or from about 12 mm to about 18 mm. As a non-limiting example, the inner diameter is about 18 mm. In some cases, the outer diameter of the chamber tube is from about 16 mm to about 28 mm, from about 18 mm to about 28 mm, from about 20 mm to about 28 mm, from about 22 mm to about 28 mm, from about 16 mm to about 26 mm, from about 16 mm to about 24 mm, or from about 16 mm to about 22 mm. As a non-limiting example, the outer diameter is about 22 mm. In some embodiments, the first fluid defining member may be permanently affixed or part of the cover or collection vessel.
The filter assembly may comprise an air permeable filter, an aromatic filter, and a filter housing. As a non-limiting example, the air permeable filter comprises a hydrophobic filter. In some cases, the filter housing is moulded in Natural ABS, e.g., as provided by Novodur FID M203FC. In some cases, the aromatic filter comprises carbon for reducing odors during NPWT. In some cases, the aromatic filter comprises from about 25 g/m2 to about 200 g/m2, from about 25 g/m2 to about 175 g/m2, from about 25 g/m2 to about 150 g/m2, from about 25 g/m2 to about 125 g/m2, from about 25 g/m2 to about 100 g/m2, from about 50 g/m2 to about 200 g/m2, or from about 75 g/m2 to about 200 g/m2 activated carbon. For example, the aromatic filter comprises about 80 g/m2, about 90 g/m2, or about 100 g/m2 activated carbon. An exemplary aromatic filter comprises activated carbon and a non-woven material with an enhanced binder. For instance, the non-woven blend comprises polyester, polyolefin, and activated carbon. As a non-limiting example, the non-woven blend comprises about 88% polyester and about 12% polyolefin, with about 90 g/m2 activated carbon (e.g., as provided by Sterling non-wovens, material number 3351).
In some embodiments, the air permeable filter has a pore size from about 0.2 microns and about 0.8 microns, or about 0.2 microns, about 0.45 microns, or about 0.8 microns. A first exemplary air permeable filter comprises polyethersulfone (PES). For example, a PES filter membrane on polyester nonwoven support, e.g., as provided by Pall, having material number S80535 (0.45 micron pore size, 0.76 mm to 0.162 mm thickness). The air permeable filter may alternatively or additional comprises polytetrafluorethylene (PTFE), cellulose acetate, cellulose nitrate membranes, or a combination thereof.
In some embodiments, the filter tube is elastomeric. In some embodiments, the filter tube is plastic. As non-limiting examples, the filter tube comprises gamma sterilisable materials such as polyvinyl chloride (PVC), silicone, ethylene propylene diene monomer (EPDM), Viton. In some cases, the filter tube comprises PVC 60 Shore A.
The apparatus may comprise a fluid inlet tube, and optionally, an extension tube. The extension tube, and/or fluid inlet tube, may comprise gamma sterilisable PVC, silicone, EPDM, Vitron, or a combination thereof. For example, the extension tube comprises PVC 60 Shore A. In some cases the extension tube attaches to the apparatus cover. In some cases, the extension tube is included in the cover moulding.
Systems and Kits
In one aspect of the disclosure, provided herein are systems comprising a fluid collection apparatus described herein and one or more accessory elements. Accessory elements include materials useful for performing a negative pressure therapy such as NPWT. In some embodiments, an accessory comprises a wound dressing. A wound dressing includes, without limitation, a dressing having a cover for sealing around a wound site and maintaining a negative pressure environment at the wound site, where the cover further comprises an adhesive for the sealing and an opening for the transfer of negative pressure. Non-limiting examples of wound dressing covers include polyurethane films having, for example, a polyurethane adhesive. In some embodiments, an accessory comprises a source of negative pressure. In some embodiments, “negative pressure” refers to pressure below atmospheric pressure. Sources of negative pressure include pumps configured to maintain a negative pressure between about 60 mmHg and about 145 mmHg below atmospheric pressure. For example, the pump may be configured to maintain a negative pressure of about 80, 100 or 125 mmHg below atmospheric pressure, ±20 mmHg. Sources of negative pressure include pumps configured to exert a maximum negative pressure of at least 200 mmHg, at least 330 mmHg or at least 400 mmHg. In exemplary embodiments, a pump is a diaphragm pump. In exemplary embodiments, a pump may be an electric pump, either mains or battery powered. The pump may be configured to operate continuously. In further exemplary embodiments, the pump may be a medical pump, such as a pump complying with Directive 93/42/EEC: IIA, IEC 60601-1 and/or IEC 60601-1-2. Additional accessory items include one or more conduits or tubings configured to connect the fluid collection apparatus to a source of negative pressure and/or wound dressing; and a connector configured to connect the outlet of the apparatus to a source of negative pressure, and connect the inlet of the apparatus to the wound dressing.
Methods
Provided herein are methods for collecting fluid using a fluid collection apparatus described herein. In some embodiments, the fluid collection apparatus utilized comprises a first fluid defining member, such as a chamber, in fluid communication with a source of negative pressure, a first impeding element positioned at a first end of the first fluid defining member, a second impeding element positioned at a second end of first fluid defining member, and a second fluid defining member, such as a fluid inlet tube, in fluid communication with a wound dressing; wherein the fluid inlet tube comprises an outlet end and the fluid inlet tube extends through the first impeding element such that the outlet of the fluid inlet tube is positioned within a fluid collection region of the fluid collection apparatus.
In one aspect, the method comprises applying a negative pressure from the source of negative pressure to the wound site via the fluid collection apparatus to draw fluid from the wound site, through the fluid inlet tube, and into the fluid collection region of the fluid collection apparatus; wherein the fluid comprises liquid and air, and the fluid is retained in the fluid collection region and the air is drawn through the first and/or the second impeding elements, into the interior of chamber tube, and towards the source of negative pressure. In some embodiments, the negative pressure applied from the negative pressure source is between about 75 mmHg and about 125 mmHg below atmospheric pressure.
In some methods, the fluid collection apparatus is positioned in an orientation-independent manner. In some cases, the fluid collection apparatus comprises multiple sides (e.g., six sides), and the fluid collection apparatus in use is: (a) positioned with any of the multiple sides against a horizontal surface and/or (b) hung or secured from an attachment point on any of the multiple sides. In some cases, the fluid collection apparatus is suspended, attached or otherwise secured from one or more attachment points on the fluid collection apparatus. In some cases, the orientation independence of an apparatus described herein is evaluated by filling the collection vessel with a liquid. In some cases, the liquid is water. In some cases, the liquid is a physiological saline solution. As a non-limiting example, the physiological saline solution is defined in EN13726-1 as Test solution A.
A fluid collection apparatus as generally depicted in
The absorbent layers (105), foam (103) and wicking sheet (104) components were stamped from roll stock. The absorbent layers comprise superabsorbent polymers. A foam sheet (103), wicking sheet (104) and the absorbent layers (105) were loaded into the canister base (111) and the filter tube (106) was placed into the canister base so that it was located by alignment features in the base of the canister and trapped the foam sheet (103) and wicking sheet (104) against the base of the canister. The absorbent layers (105) were free to slide over the chamber tube (102). A foam sheet (103) and wicking sheet (104) were fitted to the canister header (110). The filter tube (106) was pressed onto the tube spigot of the filter housing of the filter sub assembly (101) and the opposite end of the filter tube (106) was pressed over the tube spigot of the header (110) so that the filter assembly (101) is connected to the header. Optionally the canister filling tube is fitted to the fluid inlet spigot on the canister header (110). The two partial assemblies (upper and lower) were brought together so that the filter assembly (101) fits within the canister tube (102) and the mating surfaces of the canister are brought together. In this example, the mating surfaces of the canister header (110) and canister base (111) have features to aid joining them together. In the case of ultrasonic welding being employed for the joining process, a weld concentrating feature is designed into one component and a receiving surface in the other. This feature pairing may be mating pair of a tongue and groove features on the mating surfaces with a small welding concentrator such as a small radius bump (0.2 to 1 mm diameter) on the end of the tongue feature to concentrate the welding energy. The assembly is typically placed in an ultrasonic welding feature and the two halves are welded together by application of ultrasonic energy to one component to forma seal with the other part. Optionally additional sealing can be provided by solvent or adhesive should this be necessary.
To test the orientation independence of the apparatus, liquid representative of wound exudate was supplied to the apparatus at rate representative of anticipated use. This test was continued until the canister reached capacity and the hydrophobic filter was obscured by liquid. This test has been conducted with the apparatus in a typical orientation, with the canister resting on its base. This test has further been conducted with the canister placed on its side and on one end of the apparatus. The most challenging orientation is with the long axis at or close to vertical as this requires fluid to travel a greater vertical distance against gravity. However, the wicking layer assists performance under these conditions, ensuring that the majority of the absorbent layers were saturated before liquid reached the hydrophobic filter within the chamber tube.
While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the inventions described herein may be employed in practicing the inventions. It is intended that the following claims define a scope of the inventions and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Number | Date | Country | Kind |
---|---|---|---|
1719014 | Nov 2017 | GB | national |
1719027 | Nov 2017 | GB | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/IB2018/001417 | 11/16/2018 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2019/097288 | 5/23/2019 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
10016537 | Menon et al. | Jul 2018 | B2 |
10046096 | Askem et al. | Aug 2018 | B2 |
10076447 | Barta et al. | Sep 2018 | B2 |
10076587 | Locke et al. | Sep 2018 | B2 |
10143784 | Walton et al. | Dec 2018 | B2 |
10426670 | von Blucher et al. | Oct 2019 | B2 |
10426747 | Johnson | Oct 2019 | B2 |
10426874 | Chien et al. | Oct 2019 | B2 |
10426875 | Blott et al. | Oct 2019 | B2 |
10426938 | Locke et al. | Oct 2019 | B2 |
10434015 | Taylor et al. | Oct 2019 | B2 |
10434142 | Niazi et al. | Oct 2019 | B2 |
10434210 | Olson et al. | Oct 2019 | B2 |
10434284 | Hanson et al. | Oct 2019 | B2 |
10449094 | Donda et al. | Oct 2019 | B2 |
D866756 | Allen et al. | Nov 2019 | S |
10463760 | Karthikeyan et al. | Nov 2019 | B2 |
10463773 | Haggstrom et al. | Nov 2019 | B2 |
10470933 | Riesinger | Nov 2019 | B2 |
10470936 | Wohlgemuth et al. | Nov 2019 | B2 |
10471122 | Shi et al. | Nov 2019 | B2 |
10471190 | Locke et al. | Nov 2019 | B2 |
10478345 | Barta et al. | Nov 2019 | B2 |
10478346 | Knutson | Nov 2019 | B2 |
10478394 | Yu | Nov 2019 | B2 |
10485707 | Sexton | Nov 2019 | B2 |
10485891 | Andrews et al. | Nov 2019 | B2 |
10485892 | Hands et al. | Nov 2019 | B2 |
10485906 | Freedman et al. | Nov 2019 | B2 |
10486135 | Yang et al. | Nov 2019 | B2 |
10492956 | Zamierowski | Dec 2019 | B2 |
10493178 | Marchant et al. | Dec 2019 | B2 |
10493184 | Collinson et al. | Dec 2019 | B2 |
10493185 | Stokes et al. | Dec 2019 | B2 |
10500099 | Hung et al. | Dec 2019 | B2 |
10500103 | Croizat et al. | Dec 2019 | B2 |
10500104 | Sookraj | Dec 2019 | B2 |
10500173 | Yang et al. | Dec 2019 | B2 |
10500235 | Wardell | Dec 2019 | B2 |
10500300 | Dybe et al. | Dec 2019 | B2 |
10500301 | Laurensou | Dec 2019 | B2 |
10500302 | Holm et al. | Dec 2019 | B2 |
10501487 | Andrews et al. | Dec 2019 | B2 |
10506928 | Locke et al. | Dec 2019 | B2 |
10507141 | Allen et al. | Dec 2019 | B2 |
10507259 | Cree et al. | Dec 2019 | B2 |
10512707 | Whalen, III et al. | Dec 2019 | B2 |
10525170 | Havenstrite et al. | Jan 2020 | B2 |
10532137 | Pratt et al. | Jan 2020 | B2 |
10532194 | Locke et al. | Jan 2020 | B2 |
10537657 | Phillips et al. | Jan 2020 | B2 |
10542936 | Goldberg et al. | Jan 2020 | B2 |
10543133 | Shaw et al. | Jan 2020 | B2 |
10543293 | Suschek | Jan 2020 | B2 |
10548777 | Locke et al. | Feb 2020 | B2 |
10549008 | Yoo | Feb 2020 | B2 |
10549016 | Bushko et al. | Feb 2020 | B2 |
10549017 | Hsiao et al. | Feb 2020 | B2 |
10555838 | Wu et al. | Feb 2020 | B2 |
10555839 | Hartwell | Feb 2020 | B2 |
10556044 | Robinson et al. | Feb 2020 | B2 |
10561533 | Hoggarth et al. | Feb 2020 | B2 |
10561536 | Holm et al. | Feb 2020 | B2 |
10568767 | Addison et al. | Feb 2020 | B2 |
10568768 | Long et al. | Feb 2020 | B2 |
10568770 | Robinson et al. | Feb 2020 | B2 |
10568771 | MacDonald et al. | Feb 2020 | B2 |
10568773 | Tuck et al. | Feb 2020 | B2 |
10568983 | Gerdes et al. | Feb 2020 | B2 |
10575991 | Dunn | Mar 2020 | B2 |
10575992 | Sarangapani et al. | Mar 2020 | B2 |
10576037 | Harrell | Mar 2020 | B2 |
10576189 | Locke et al. | Mar 2020 | B2 |
10583042 | Sarangapani et al. | Mar 2020 | B2 |
10583228 | Shuler et al. | Mar 2020 | B2 |
10589007 | Coulthard et al. | Mar 2020 | B2 |
10590184 | Kuo | Mar 2020 | B2 |
10610414 | Hartwell et al. | Apr 2020 | B2 |
10610415 | Griffey et al. | Apr 2020 | B2 |
10610623 | Robinson et al. | Apr 2020 | B2 |
10617569 | Bonn | Apr 2020 | B2 |
10617608 | Shin et al. | Apr 2020 | B2 |
10617769 | Huang | Apr 2020 | B2 |
10617784 | Yu et al. | Apr 2020 | B2 |
10617786 | Kluge et al. | Apr 2020 | B2 |
10618266 | Wright et al. | Apr 2020 | B2 |
10624984 | Courage et al. | Apr 2020 | B2 |
10625002 | Locke et al. | Apr 2020 | B2 |
10632019 | Vitaris | Apr 2020 | B2 |
10632224 | Hardy et al. | Apr 2020 | B2 |
10639206 | Hu et al. | May 2020 | B2 |
10639350 | Arber et al. | May 2020 | B2 |
10639404 | Lichtenstein | May 2020 | B2 |
10646614 | Grinstaff et al. | May 2020 | B2 |
10653562 | Robinson et al. | May 2020 | B2 |
10653782 | Ameer et al. | May 2020 | B2 |
10653810 | Datt et al. | May 2020 | B2 |
10653821 | Nichols | May 2020 | B2 |
10653823 | Bharti et al. | May 2020 | B2 |
10660799 | Wu et al. | May 2020 | B2 |
10660851 | Millis et al. | May 2020 | B2 |
10660992 | Canner et al. | May 2020 | B2 |
10660994 | Askem et al. | May 2020 | B2 |
10667955 | Allen et al. | Jun 2020 | B2 |
10667956 | Van Holten et al. | Jun 2020 | B2 |
10682257 | Lu | Jun 2020 | B2 |
10682258 | Manwaring et al. | Jun 2020 | B2 |
10682259 | Hunt et al. | Jun 2020 | B2 |
10682318 | Twomey et al. | Jun 2020 | B2 |
10682386 | Ellis-Behnke et al. | Jun 2020 | B2 |
10682446 | Askem et al. | Jun 2020 | B2 |
10687983 | Dahlberg et al. | Jun 2020 | B2 |
10687985 | Lee et al. | Jun 2020 | B2 |
10688215 | Munro et al. | Jun 2020 | B2 |
10688217 | Hanson et al. | Jun 2020 | B2 |
RE48117 | Albert et al. | Jul 2020 | E |
10702419 | Locke et al. | Jul 2020 | B2 |
10702420 | Hammond et al. | Jul 2020 | B2 |
10703942 | Tunius | Jul 2020 | B2 |
10709760 | Gronberg et al. | Jul 2020 | B2 |
10709807 | Kshirsagar | Jul 2020 | B2 |
10709883 | Spector | Jul 2020 | B2 |
10716711 | Locke et al. | Jul 2020 | B2 |
10716874 | Koyama et al. | Jul 2020 | B2 |
10729589 | Dorian et al. | Aug 2020 | B2 |
10729590 | Simmons et al. | Aug 2020 | B2 |
10729826 | Lin | Aug 2020 | B2 |
10736787 | Hannigan et al. | Aug 2020 | B2 |
10736788 | Locke et al. | Aug 2020 | B2 |
10736985 | Odermatt et al. | Aug 2020 | B2 |
10737003 | Fujisaki | Aug 2020 | B2 |
10743900 | Ingram et al. | Aug 2020 | B2 |
10744040 | Kazala, Jr. et al. | Aug 2020 | B2 |
10744041 | Hartwell | Aug 2020 | B2 |
10744225 | Lindgren et al. | Aug 2020 | B2 |
10744237 | Guidi et al. | Aug 2020 | B2 |
10744238 | Guidi et al. | Aug 2020 | B2 |
10744239 | Armstrong et al. | Aug 2020 | B2 |
10744240 | Simmons et al. | Aug 2020 | B2 |
10751212 | Raza et al. | Aug 2020 | B2 |
10751442 | Bonnefin et al. | Aug 2020 | B2 |
10751452 | Topaz | Aug 2020 | B2 |
10758423 | Pigg et al. | Sep 2020 | B2 |
10758424 | Blott et al. | Sep 2020 | B2 |
10758425 | Blott et al. | Sep 2020 | B2 |
10758426 | Eddy | Sep 2020 | B2 |
10758651 | Blott et al. | Sep 2020 | B2 |
10765561 | Lattimore et al. | Sep 2020 | B2 |
10765783 | Locke et al. | Sep 2020 | B2 |
10772767 | Bjork et al. | Sep 2020 | B2 |
10772999 | Svensby | Sep 2020 | B2 |
10779993 | Bishop et al. | Sep 2020 | B2 |
10780114 | Udagawa et al. | Sep 2020 | B2 |
10780194 | Flach et al. | Sep 2020 | B2 |
10780201 | Lin | Sep 2020 | B2 |
10780202 | Askem et al. | Sep 2020 | B2 |
10780203 | Coulthard et al. | Sep 2020 | B2 |
10782238 | Hicks et al. | Sep 2020 | B2 |
10792191 | Robinson et al. | Oct 2020 | B2 |
10792192 | Tout et al. | Oct 2020 | B2 |
10792337 | Leung et al. | Oct 2020 | B2 |
10792404 | Hu et al. | Oct 2020 | B2 |
10792482 | Randolph et al. | Oct 2020 | B2 |
10800905 | Delli-Santi et al. | Oct 2020 | B2 |
10806819 | Shuler | Oct 2020 | B2 |
11026847 | Piotrowski et al. | Jun 2021 | B2 |
11058587 | Adie et al. | Jul 2021 | B2 |
11058588 | Albert et al. | Jul 2021 | B2 |
11071652 | Donda et al. | Jul 2021 | B2 |
11071653 | Hunt | Jul 2021 | B2 |
11076997 | Hunt et al. | Aug 2021 | B2 |
11083884 | Robinson et al. | Aug 2021 | B2 |
11090195 | Adie et al. | Aug 2021 | B2 |
11096829 | Robinson et al. | Aug 2021 | B2 |
11123476 | Hunt et al. | Sep 2021 | B2 |
11123537 | Luckemeyer et al. | Sep 2021 | B2 |
11135342 | Pratt et al. | Oct 2021 | B2 |
11141521 | Beadle et al. | Oct 2021 | B2 |
11154426 | Riesinger | Oct 2021 | B2 |
11154649 | Collinson et al. | Oct 2021 | B2 |
11179276 | Hartwell | Nov 2021 | B2 |
11179512 | Locke et al. | Nov 2021 | B2 |
11191887 | Locke et al. | Dec 2021 | B2 |
11197953 | Heaton et al. | Dec 2021 | B2 |
11207442 | Locke et al. | Dec 2021 | B2 |
11207458 | Locke et al. | Dec 2021 | B2 |
11246758 | Hardman et al. | Feb 2022 | B2 |
11246975 | Locke et al. | Feb 2022 | B2 |
11253400 | Zochowski et al. | Feb 2022 | B2 |
11253401 | Pratt et al. | Feb 2022 | B2 |
11266537 | Robinson et al. | Mar 2022 | B2 |
11266774 | Selby et al. | Mar 2022 | B2 |
11278454 | Edwards et al. | Mar 2022 | B2 |
11298268 | Jardret et al. | Apr 2022 | B2 |
11298454 | Weston | Apr 2022 | B2 |
11318243 | Robinson et al. | May 2022 | B2 |
11351063 | Locke et al. | Jun 2022 | B2 |
11351064 | Hartwell | Jun 2022 | B2 |
11364151 | Hartwell | Jun 2022 | B2 |
11364334 | Long et al. | Jun 2022 | B2 |
11864980 | Locke et al. | Jan 2024 | B2 |
11864981 | Allen et al. | Jan 2024 | B2 |
11878102 | Cornet et al. | Jan 2024 | B2 |
11883261 | Coulthard et al. | Jan 2024 | B2 |
11883262 | Cole et al. | Jan 2024 | B2 |
11883577 | Selby et al. | Jan 2024 | B2 |
11883578 | Locke et al. | Jan 2024 | B2 |
11890437 | Luckemeyer et al. | Feb 2024 | B2 |
11896465 | Askem et al. | Feb 2024 | B2 |
11903798 | Askem et al. | Feb 2024 | B2 |
11911556 | Mercer et al. | Feb 2024 | B2 |
11925735 | Gowans et al. | Mar 2024 | B2 |
11931165 | Askem et al. | Mar 2024 | B2 |
11938002 | Hunt et al. | Mar 2024 | B2 |
11944519 | Zurovcik | Apr 2024 | B2 |
11944520 | Locke et al. | Apr 2024 | B2 |
11957545 | Hunt et al. | Apr 2024 | B2 |
11957829 | Coulthard et al. | Apr 2024 | B2 |
11963850 | Freedman et al. | Apr 2024 | B2 |
11964093 | Greener | Apr 2024 | B2 |
11969541 | Gordon et al. | Apr 2024 | B2 |
11974902 | Greener | May 2024 | B2 |
11975134 | Quintanar | May 2024 | B2 |
11992392 | Earl et al. | May 2024 | B2 |
11992601 | Vess et al. | May 2024 | B2 |
12004925 | Hartwell | Jun 2024 | B2 |
12016991 | Coulthard et al. | Jun 2024 | B2 |
20060155260 | Blott et al. | Jul 2006 | A1 |
20060172000 | Cullen et al. | Aug 2006 | A1 |
20070185426 | Ambrosio et al. | Aug 2007 | A1 |
20070219512 | Heaton et al. | Sep 2007 | A1 |
20070239078 | Jaeb | Oct 2007 | A1 |
20080071214 | Locke | Mar 2008 | A1 |
20090234307 | Vitaris | Sep 2009 | A1 |
20090259203 | Hu et al. | Oct 2009 | A1 |
20090292263 | Hudspeth et al. | Nov 2009 | A1 |
20090293887 | Wilkes et al. | Dec 2009 | A1 |
20090299303 | Seegert | Dec 2009 | A1 |
20090306630 | Locke et al. | Dec 2009 | A1 |
20100015208 | Kershaw et al. | Jan 2010 | A1 |
20100030178 | MacMeccan et al. | Feb 2010 | A1 |
20100125233 | Edward S. et al. | May 2010 | A1 |
20100125258 | Coulthard et al. | May 2010 | A1 |
20100137775 | Hu et al. | Jun 2010 | A1 |
20100179493 | Heagle | Jul 2010 | A1 |
20100185163 | Heagle | Jul 2010 | A1 |
20100286638 | Malhi | Nov 2010 | A1 |
20100298790 | Guidi et al. | Nov 2010 | A1 |
20100318071 | Wudyka | Dec 2010 | A1 |
20110015595 | Robinson et al. | Jan 2011 | A1 |
20110028918 | Hartwell | Feb 2011 | A1 |
20110112457 | Holm et al. | May 2011 | A1 |
20110178451 | Robinson et al. | Jul 2011 | A1 |
20110224593 | Tunius | Sep 2011 | A1 |
20110224630 | Simmons et al. | Sep 2011 | A1 |
20110230849 | Coulthard et al. | Sep 2011 | A1 |
20110251566 | Zimnitsky et al. | Oct 2011 | A1 |
20110257572 | Locke et al. | Oct 2011 | A1 |
20110257573 | Hong et al. | Oct 2011 | A1 |
20110275972 | Rosenberg | Nov 2011 | A1 |
20120071845 | Hu et al. | Mar 2012 | A1 |
20120130332 | Cotton et al. | May 2012 | A1 |
20120136325 | Allen et al. | May 2012 | A1 |
20120209226 | Simmons et al. | Aug 2012 | A1 |
20130053795 | Coulthard et al. | Feb 2013 | A1 |
20130053797 | Locke | Feb 2013 | A1 |
20130066301 | Locke | Mar 2013 | A1 |
20130123728 | Pratt et al. | May 2013 | A1 |
20130226063 | Taylor et al. | Aug 2013 | A1 |
20140005618 | Locke et al. | Jan 2014 | A1 |
20140074053 | Locke | Mar 2014 | A1 |
20140188060 | Robinson et al. | Jul 2014 | A1 |
20140194838 | Wibaux et al. | Jul 2014 | A1 |
20140200532 | Robinson et al. | Jul 2014 | A1 |
20140236112 | Von Wolff et al. | Aug 2014 | A1 |
20140256925 | Catchmark et al. | Sep 2014 | A1 |
20140276497 | Robinson | Sep 2014 | A1 |
20140276499 | Locke et al. | Sep 2014 | A1 |
20140296804 | Hicks et al. | Oct 2014 | A1 |
20140308338 | Nierle et al. | Oct 2014 | A1 |
20140309574 | Cotton | Oct 2014 | A1 |
20150018433 | Leipzig et al. | Jan 2015 | A1 |
20150057624 | Simmons et al. | Feb 2015 | A1 |
20150071985 | Walker et al. | Mar 2015 | A1 |
20150079152 | Wuollett et al. | Mar 2015 | A1 |
20150094674 | Pratt et al. | Apr 2015 | A1 |
20150104486 | Bonnefin et al. | Apr 2015 | A1 |
20150112311 | Hammond et al. | Apr 2015 | A1 |
20150119831 | Robinson et al. | Apr 2015 | A1 |
20150119834 | Locke et al. | Apr 2015 | A1 |
20150141941 | Allen et al. | May 2015 | A1 |
20150148785 | Kleiner | May 2015 | A1 |
20150174304 | Askem et al. | Jun 2015 | A1 |
20150245949 | Locke et al. | Sep 2015 | A1 |
20150246164 | Heaton et al. | Sep 2015 | A1 |
20150250979 | Loske | Sep 2015 | A1 |
20150265741 | Duncan et al. | Sep 2015 | A1 |
20150265743 | Hanson et al. | Sep 2015 | A1 |
20150320901 | Chandrashekhar-Bhat et al. | Nov 2015 | A1 |
20160008293 | Shi et al. | Jan 2016 | A1 |
20160038626 | Locke et al. | Feb 2016 | A1 |
20160051724 | Sahin et al. | Feb 2016 | A1 |
20160067107 | Cotton | Mar 2016 | A1 |
20160100987 | Hartwell et al. | Apr 2016 | A1 |
20160106878 | Yang et al. | Apr 2016 | A1 |
20160106892 | Hartwell | Apr 2016 | A1 |
20160114281 | Bonano | Apr 2016 | A1 |
20160166422 | Karim et al. | Jun 2016 | A1 |
20160193244 | Ota et al. | Jul 2016 | A1 |
20160222548 | Agboh | Aug 2016 | A1 |
20160271178 | Hauser et al. | Sep 2016 | A1 |
20160287743 | Andrews | Oct 2016 | A1 |
20160339158 | Collinson et al. | Nov 2016 | A1 |
20160374847 | Lachenbruch et al. | Dec 2016 | A1 |
20170014275 | Schneider | Jan 2017 | A1 |
20170049111 | Patton et al. | Feb 2017 | A1 |
20170072669 | Sekido et al. | Mar 2017 | A1 |
20170128269 | Coulthard et al. | May 2017 | A1 |
20170189237 | Locke et al. | Jul 2017 | A1 |
20170189575 | Lee et al. | Jul 2017 | A1 |
20170209615 | Tornero Garcia et al. | Jul 2017 | A1 |
20170232161 | Fewkes et al. | Aug 2017 | A1 |
20170258956 | Flach et al. | Sep 2017 | A1 |
20170367895 | Holm et al. | Dec 2017 | A1 |
20170368239 | Askem et al. | Dec 2017 | A1 |
20180008742 | Hoggarth et al. | Jan 2018 | A1 |
20180014974 | Hoggarth et al. | Jan 2018 | A1 |
20180023217 | Patton et al. | Jan 2018 | A1 |
20180030321 | Tunius | Feb 2018 | A1 |
20180042789 | Bradford et al. | Feb 2018 | A1 |
20180078423 | Magin et al. | Mar 2018 | A1 |
20180086903 | Zhang et al. | Mar 2018 | A1 |
20180118809 | Mearns Spragg | May 2018 | A1 |
20180133066 | Ahsani et al. | May 2018 | A1 |
20180140467 | Hunt | May 2018 | A1 |
20180140822 | Robinson et al. | May 2018 | A1 |
20180200414 | Askem et al. | Jul 2018 | A1 |
20180221531 | Bender et al. | Aug 2018 | A1 |
20180236124 | Young et al. | Aug 2018 | A1 |
20180243463 | Chatterjee et al. | Aug 2018 | A1 |
20180243464 | Hwang et al. | Aug 2018 | A1 |
20180244857 | Lee et al. | Aug 2018 | A1 |
20180272052 | Locke et al. | Sep 2018 | A1 |
20180296397 | Askem et al. | Oct 2018 | A1 |
20180303873 | Been et al. | Oct 2018 | A1 |
20180311419 | Locke et al. | Nov 2018 | A1 |
20180333522 | Pratt et al. | Nov 2018 | A1 |
20180344533 | Rovaniemi | Dec 2018 | A1 |
20180353334 | Locke et al. | Dec 2018 | A1 |
20180353337 | Locke | Dec 2018 | A1 |
20180353339 | Locke et al. | Dec 2018 | A1 |
20180353340 | Robinson et al. | Dec 2018 | A1 |
20180353344 | Locke et al. | Dec 2018 | A1 |
20180353662 | Locke et al. | Dec 2018 | A1 |
20180353663 | Locke et al. | Dec 2018 | A1 |
20180360667 | Droche | Dec 2018 | A1 |
20190000677 | Munro | Jan 2019 | A1 |
20190001030 | Braga | Jan 2019 | A1 |
20190015258 | Gowans et al. | Jan 2019 | A1 |
20190015468 | Yadav et al. | Jan 2019 | A1 |
20190030223 | Lin | Jan 2019 | A1 |
20190046682 | Choi et al. | Feb 2019 | A1 |
20190060127 | Locke et al. | Feb 2019 | A1 |
20190083752 | Howell et al. | Mar 2019 | A1 |
20190117465 | Osborne et al. | Apr 2019 | A1 |
20190117466 | Kazala, Jr. et al. | Apr 2019 | A1 |
20190117861 | Locke et al. | Apr 2019 | A1 |
20190125590 | Rehbein et al. | May 2019 | A1 |
20190133830 | Bishop et al. | May 2019 | A1 |
20190151155 | Bonn | May 2019 | A1 |
20190151159 | Gowans et al. | May 2019 | A1 |
20190151495 | Helary et al. | May 2019 | A1 |
20190184052 | Ilan et al. | Jun 2019 | A1 |
20190231600 | Locke et al. | Aug 2019 | A1 |
20190231602 | Locke et al. | Aug 2019 | A1 |
20190231943 | Robinson et al. | Aug 2019 | A1 |
20190274889 | Steward et al. | Sep 2019 | A1 |
20190282728 | Kellar et al. | Sep 2019 | A1 |
20190290799 | Arshi et al. | Sep 2019 | A1 |
20190298249 | Bates et al. | Oct 2019 | A1 |
20190298577 | Locke et al. | Oct 2019 | A1 |
20190298578 | Shulman et al. | Oct 2019 | A1 |
20190298579 | Moore et al. | Oct 2019 | A1 |
20190298580 | Hall et al. | Oct 2019 | A1 |
20190298582 | Addison et al. | Oct 2019 | A1 |
20190298881 | Ramjit et al. | Oct 2019 | A1 |
20190298882 | Nelson | Oct 2019 | A1 |
20190298895 | Selby et al. | Oct 2019 | A1 |
20190307611 | Askem et al. | Oct 2019 | A1 |
20190307612 | Hartwell et al. | Oct 2019 | A1 |
20190307934 | Allen et al. | Oct 2019 | A1 |
20190307935 | Simmons et al. | Oct 2019 | A1 |
20190314187 | Emslander et al. | Oct 2019 | A1 |
20190314209 | Ha et al. | Oct 2019 | A1 |
20190314544 | Filho et al. | Oct 2019 | A1 |
20190321232 | Jardret et al. | Oct 2019 | A1 |
20190321509 | Chakravarthy et al. | Oct 2019 | A1 |
20190321526 | Robinson et al. | Oct 2019 | A1 |
20190322795 | Kubo et al. | Oct 2019 | A1 |
20190328580 | Emslander et al. | Oct 2019 | A1 |
20190336343 | Etchells et al. | Nov 2019 | A1 |
20190336344 | Locke | Nov 2019 | A1 |
20190336345 | Bannwart | Nov 2019 | A1 |
20190336346 | Locke et al. | Nov 2019 | A1 |
20190336640 | Vismara et al. | Nov 2019 | A1 |
20190336641 | Nisbet | Nov 2019 | A1 |
20190336643 | Luukko et al. | Nov 2019 | A1 |
20190336658 | Heaton et al. | Nov 2019 | A1 |
20190336739 | Locke et al. | Nov 2019 | A1 |
20190343687 | Locke et al. | Nov 2019 | A1 |
20190343889 | Luukko et al. | Nov 2019 | A1 |
20190343979 | Kearney et al. | Nov 2019 | A1 |
20190343993 | Weston | Nov 2019 | A1 |
20190343994 | Greener | Nov 2019 | A1 |
20190344242 | Kim et al. | Nov 2019 | A1 |
20190350763 | Pratt et al. | Nov 2019 | A1 |
20190350764 | Zochowski et al. | Nov 2019 | A1 |
20190350765 | Heagle et al. | Nov 2019 | A1 |
20190350775 | Biasutti et al. | Nov 2019 | A1 |
20190350970 | Saphier et al. | Nov 2019 | A1 |
20190351092 | Silver et al. | Nov 2019 | A1 |
20190351093 | Stein et al. | Nov 2019 | A1 |
20190351094 | Maher et al. | Nov 2019 | A1 |
20190351095 | Maher et al. | Nov 2019 | A1 |
20190351111 | Locke et al. | Nov 2019 | A1 |
20190358088 | Lavocah et al. | Nov 2019 | A1 |
20190358361 | McInnes et al. | Nov 2019 | A1 |
20190358372 | Askem et al. | Nov 2019 | A1 |
20190365948 | Deegan et al. | Dec 2019 | A1 |
20190365962 | Lee et al. | Dec 2019 | A1 |
20190374408 | Robles et al. | Dec 2019 | A1 |
20190374673 | Hoefinghoff et al. | Dec 2019 | A1 |
20190380878 | Edwards et al. | Dec 2019 | A1 |
20190380881 | Albert et al. | Dec 2019 | A1 |
20190380882 | Taylor et al. | Dec 2019 | A1 |
20190380883 | Macphee et al. | Dec 2019 | A1 |
20190381222 | Locke et al. | Dec 2019 | A9 |
20190388577 | Chandrashekhar-Bhat et al. | Dec 2019 | A1 |
20190388579 | Macphee et al. | Dec 2019 | A1 |
20190388589 | Macphee et al. | Dec 2019 | A1 |
20200000640 | Mondal et al. | Jan 2020 | A1 |
20200000642 | Waite | Jan 2020 | A1 |
20200000643 | Locke | Jan 2020 | A1 |
20200000955 | Andrews et al. | Jan 2020 | A1 |
20200000956 | Huang et al. | Jan 2020 | A1 |
20200000960 | Kellar et al. | Jan 2020 | A1 |
20200000985 | Seddon et al. | Jan 2020 | A1 |
20200008981 | Wheldrake | Jan 2020 | A1 |
20200009289 | Torabinejad et al. | Jan 2020 | A1 |
20200009400 | Ribeiro et al. | Jan 2020 | A1 |
20200017650 | Young et al. | Jan 2020 | A1 |
20200022844 | Blott et al. | Jan 2020 | A1 |
20200023102 | Powell | Jan 2020 | A1 |
20200023103 | Joshi et al. | Jan 2020 | A1 |
20200023104 | Eriksson et al. | Jan 2020 | A1 |
20200023105 | Long et al. | Jan 2020 | A1 |
20200023106 | Carroll et al. | Jan 2020 | A1 |
20200030153 | Johannison et al. | Jan 2020 | A1 |
20200030480 | Choi | Jan 2020 | A1 |
20200030499 | Menon et al. | Jan 2020 | A1 |
20200038023 | Dunn | Feb 2020 | A1 |
20200038249 | Pratt et al. | Feb 2020 | A1 |
20200038250 | Edwards et al. | Feb 2020 | A1 |
20200038251 | Locke et al. | Feb 2020 | A1 |
20200038252 | Spiro | Feb 2020 | A1 |
20200038283 | Hall et al. | Feb 2020 | A1 |
20200038470 | Datt et al. | Feb 2020 | A1 |
20200038544 | Grover et al. | Feb 2020 | A1 |
20200038546 | Dizio et al. | Feb 2020 | A1 |
20200038639 | Patel et al. | Feb 2020 | A1 |
20200046565 | Barta et al. | Feb 2020 | A1 |
20200046566 | Carey et al. | Feb 2020 | A1 |
20200046567 | Carroll et al. | Feb 2020 | A1 |
20200046568 | Sexton | Feb 2020 | A1 |
20200046663 | Murdock et al. | Feb 2020 | A1 |
20200046876 | Liu | Feb 2020 | A1 |
20200046887 | Runquist et al. | Feb 2020 | A1 |
20200054491 | Hentrich et al. | Feb 2020 | A1 |
20200054781 | Weiser et al. | Feb 2020 | A1 |
20200060879 | Edwards et al. | Feb 2020 | A1 |
20200061253 | Long et al. | Feb 2020 | A1 |
20200061254 | Joshi et al. | Feb 2020 | A1 |
20200061379 | Bogie et al. | Feb 2020 | A1 |
20200069183 | Rice et al. | Mar 2020 | A1 |
20200069476 | Randolph et al. | Mar 2020 | A1 |
20200069477 | Holm et al. | Mar 2020 | A1 |
20200069478 | Jabbarzadeh et al. | Mar 2020 | A1 |
20200069479 | Buan et al. | Mar 2020 | A1 |
20200069835 | Hissink et al. | Mar 2020 | A1 |
20200069850 | Beadle et al. | Mar 2020 | A1 |
20200069851 | Blott et al. | Mar 2020 | A1 |
20200069853 | Hall et al. | Mar 2020 | A1 |
20200078223 | Locke et al. | Mar 2020 | A1 |
20200078224 | Carroll et al. | Mar 2020 | A1 |
20200078225 | Grillitsch et al. | Mar 2020 | A1 |
20200078305 | Auvinen et al. | Mar 2020 | A1 |
20200078330 | Gay | Mar 2020 | A1 |
20200078482 | Yoon et al. | Mar 2020 | A1 |
20200078499 | Gadde et al. | Mar 2020 | A1 |
20200085625 | Bellini et al. | Mar 2020 | A1 |
20200085626 | Braga et al. | Mar 2020 | A1 |
20200085629 | Locke et al. | Mar 2020 | A1 |
20200085630 | Robinson et al. | Mar 2020 | A1 |
20200085632 | Locke et al. | Mar 2020 | A1 |
20200085991 | Coomber | Mar 2020 | A1 |
20200085992 | Locke et al. | Mar 2020 | A1 |
20200086014 | Locke et al. | Mar 2020 | A1 |
20200086017 | Jardret et al. | Mar 2020 | A1 |
20200086049 | Park et al. | Mar 2020 | A1 |
20200093646 | Locke et al. | Mar 2020 | A1 |
20200093756 | Sabacinski | Mar 2020 | A1 |
20200093953 | Kim et al. | Mar 2020 | A1 |
20200093954 | Leise, III | Mar 2020 | A1 |
20200093970 | Hunt et al. | Mar 2020 | A1 |
20200095421 | Kettel | Mar 2020 | A1 |
20200100945 | Albert et al. | Apr 2020 | A1 |
20200101192 | Folwarzny | Apr 2020 | A1 |
20200107964 | Locke et al. | Apr 2020 | A1 |
20200107965 | Greener | Apr 2020 | A1 |
20200107966 | Francis | Apr 2020 | A1 |
20200107967 | Holm et al. | Apr 2020 | A1 |
20200108169 | Hu et al. | Apr 2020 | A1 |
20200113741 | Rehbein et al. | Apr 2020 | A1 |
20200114039 | Wang et al. | Apr 2020 | A1 |
20200114040 | Waite et al. | Apr 2020 | A1 |
20200114049 | Wall | Apr 2020 | A1 |
20200121509 | Locke et al. | Apr 2020 | A1 |
20200121510 | Hartwell et al. | Apr 2020 | A1 |
20200121513 | Townsend et al. | Apr 2020 | A1 |
20200121521 | Daniel et al. | Apr 2020 | A1 |
20200121833 | Askem et al. | Apr 2020 | A9 |
20200129338 | Gardiner et al. | Apr 2020 | A1 |
20200129341 | Coulthard et al. | Apr 2020 | A1 |
20200129648 | Drury et al. | Apr 2020 | A1 |
20200129654 | Bouvier et al. | Apr 2020 | A1 |
20200129655 | Gardiner et al. | Apr 2020 | A1 |
20200129675 | Robinson et al. | Apr 2020 | A1 |
20200138754 | Johnson | May 2020 | A1 |
20200139002 | Dudnyk et al. | May 2020 | A1 |
20200139023 | Haggstrom et al. | May 2020 | A1 |
20200139025 | Robinson et al. | May 2020 | A1 |
20200141031 | Kosan et al. | May 2020 | A1 |
20200146894 | Long et al. | May 2020 | A1 |
20200146896 | Rice et al. | May 2020 | A1 |
20200146897 | Locke et al. | May 2020 | A1 |
20200146899 | Pratt et al. | May 2020 | A1 |
20200155355 | Hill et al. | May 2020 | A1 |
20200155358 | Wheldrake | May 2020 | A1 |
20200155359 | Carroll et al. | May 2020 | A1 |
20200155361 | Pigg et al. | May 2020 | A1 |
20200155379 | Shaw et al. | May 2020 | A1 |
20200163802 | Hunt et al. | May 2020 | A1 |
20200163803 | Pigg et al. | May 2020 | A1 |
20200164112 | Kato et al. | May 2020 | A1 |
20200164120 | Jaecklein et al. | May 2020 | A1 |
20200170841 | Waite et al. | Jun 2020 | A1 |
20200170842 | Locke | Jun 2020 | A1 |
20200170843 | Collinson et al. | Jun 2020 | A1 |
20200171197 | Hubbell et al. | Jun 2020 | A1 |
20200179300 | Urban et al. | Jun 2020 | A1 |
20200179558 | Munro et al. | Jun 2020 | A1 |
20200179673 | Wan | Jun 2020 | A1 |
20200188179 | Bugedo-Albizuri et al. | Jun 2020 | A1 |
20200188180 | Akbari et al. | Jun 2020 | A1 |
20200188182 | Sanders et al. | Jun 2020 | A1 |
20200188183 | Hamerslagh et al. | Jun 2020 | A1 |
20200188550 | Dagger et al. | Jun 2020 | A1 |
20200188564 | Dunn | Jun 2020 | A1 |
20200190310 | Meyer | Jun 2020 | A1 |
20200197227 | Locke et al. | Jun 2020 | A1 |
20200197228 | Hartwell | Jun 2020 | A1 |
20200197559 | Bourdillon et al. | Jun 2020 | A1 |
20200197580 | Kilpadi et al. | Jun 2020 | A1 |
20200206035 | Kantor et al. | Jul 2020 | A1 |
20200206036 | Robinson et al. | Jul 2020 | A1 |
20200214637 | Brownhill et al. | Jul 2020 | A1 |
20200214897 | Long et al. | Jul 2020 | A1 |
20200214898 | Waite et al. | Jul 2020 | A1 |
20200214899 | Locke et al. | Jul 2020 | A1 |
20200215220 | Schomburg et al. | Jul 2020 | A1 |
20200215226 | Kitagawa et al. | Jul 2020 | A1 |
20200222469 | Cotton | Jul 2020 | A1 |
20200229983 | Robinson et al. | Jul 2020 | A1 |
20200230283 | Yang et al. | Jul 2020 | A1 |
20200237562 | Rice et al. | Jul 2020 | A1 |
20200237564 | Hammond et al. | Jul 2020 | A1 |
20200237816 | Lait | Jul 2020 | A1 |
20200246190 | Luckemeyer et al. | Aug 2020 | A1 |
20200246191 | Lu et al. | Aug 2020 | A1 |
20200246194 | Gonzalez et al. | Aug 2020 | A1 |
20200246195 | Robinson et al. | Aug 2020 | A1 |
20200253785 | Bernet et al. | Aug 2020 | A1 |
20200253786 | Harrison et al. | Aug 2020 | A1 |
20200253788 | Rehbein et al. | Aug 2020 | A1 |
20200254139 | Phillips et al. | Aug 2020 | A1 |
20200261275 | Manwaring et al. | Aug 2020 | A1 |
20200261276 | Lujan Hernandez et al. | Aug 2020 | A1 |
20200268560 | Harrison et al. | Aug 2020 | A1 |
20200268561 | Locke et al. | Aug 2020 | A1 |
20200269028 | Hegg | Aug 2020 | A1 |
20200270484 | Lipscomb et al. | Aug 2020 | A1 |
20200276055 | Randolph et al. | Sep 2020 | A1 |
20200276058 | Locke et al. | Sep 2020 | A1 |
20200277450 | Silverstein et al. | Sep 2020 | A1 |
20200281519 | Gowans et al. | Sep 2020 | A1 |
20200281529 | Grubb et al. | Sep 2020 | A1 |
20200281678 | Long et al. | Sep 2020 | A1 |
20200281775 | Kushnir et al. | Sep 2020 | A1 |
20200282100 | Gil et al. | Sep 2020 | A1 |
20200282114 | Long et al. | Sep 2020 | A1 |
20200282115 | Gardner et al. | Sep 2020 | A1 |
20200289326 | Nielsen et al. | Sep 2020 | A1 |
20200289327 | Hansen et al. | Sep 2020 | A1 |
20200289328 | Luckemeyer et al. | Sep 2020 | A1 |
20200289346 | Hansen et al. | Sep 2020 | A1 |
20200289347 | Gowans et al. | Sep 2020 | A1 |
20200289701 | Hall et al. | Sep 2020 | A1 |
20200289712 | Jiang et al. | Sep 2020 | A1 |
20200289723 | Gregory et al. | Sep 2020 | A1 |
20200289726 | Locke et al. | Sep 2020 | A1 |
20200289727 | Locke | Sep 2020 | A1 |
20200289806 | Locke et al. | Sep 2020 | A1 |
20200297541 | Hartwell et al. | Sep 2020 | A1 |
20200297543 | Rodzewicz et al. | Sep 2020 | A1 |
20200297544 | Moine et al. | Sep 2020 | A1 |
20200297892 | Silcock | Sep 2020 | A1 |
20200297893 | Ericson | Sep 2020 | A1 |
20200297894 | Koyama et al. | Sep 2020 | A1 |
20200299865 | Bonnefin et al. | Sep 2020 | A1 |
20200306089 | Delury et al. | Oct 2020 | A1 |
20200306091 | Lee et al. | Oct 2020 | A1 |
20200306092 | Rehbein et al. | Oct 2020 | A1 |
20200306094 | Kushnir et al. | Oct 2020 | A1 |
20200306426 | Rice et al. | Oct 2020 | A1 |
20200306428 | Ingram et al. | Oct 2020 | A1 |
20200306430 | Rehbein et al. | Oct 2020 | A1 |
20200315853 | Waite | Oct 2020 | A1 |
20200315854 | Simmons et al. | Oct 2020 | A1 |
20200315894 | Churilla et al. | Oct 2020 | A1 |
20200316271 | Lin | Oct 2020 | A1 |
20200316272 | Simpson | Oct 2020 | A1 |
20200316273 | Hegg | Oct 2020 | A1 |
20200323692 | Locke et al. | Oct 2020 | A1 |
20200324015 | Kettel et al. | Oct 2020 | A1 |
20200330283 | Locke et al. | Oct 2020 | A1 |
20200330284 | Locke et al. | Oct 2020 | A1 |
20200330285 | Rehbein et al. | Oct 2020 | A1 |
20200330658 | Fujisaki | Oct 2020 | A1 |
20200330660 | Patel et al. | Oct 2020 | A1 |
20200337719 | Ingram et al. | Oct 2020 | A1 |
20200337904 | Waite | Oct 2020 | A1 |
20200337905 | Earl et al. | Oct 2020 | A1 |
20200337906 | Long et al. | Oct 2020 | A1 |
20200337908 | Long et al. | Oct 2020 | A1 |
20200338228 | Kharkar et al. | Oct 2020 | A1 |
20200338243 | Harrison et al. | Oct 2020 | A1 |
20210170066 | Buan et al. | Jun 2021 | A1 |
20210187171 | Collinson et al. | Jun 2021 | A1 |
20210187174 | Locke | Jun 2021 | A1 |
20210196868 | Robinson et al. | Jul 2021 | A1 |
20210236342 | Long et al. | Aug 2021 | A1 |
20210252208 | Childress et al. | Aug 2021 | A1 |
20210275736 | Locke et al. | Sep 2021 | A1 |
20210290837 | Brandolini et al. | Sep 2021 | A1 |
20210322666 | Greener | Oct 2021 | A1 |
20210330956 | Robinson et al. | Oct 2021 | A1 |
20210338486 | Dagger et al. | Nov 2021 | A1 |
20210338487 | Robinson et al. | Nov 2021 | A1 |
20210353470 | Donda et al. | Nov 2021 | A1 |
20210361852 | Locke et al. | Nov 2021 | A1 |
20210361854 | Askem et al. | Nov 2021 | A1 |
20210370043 | Luckemeyer et al. | Dec 2021 | A1 |
20210378876 | Gowans | Dec 2021 | A1 |
20210379273 | Locke et al. | Dec 2021 | A1 |
20220000670 | Adie et al. | Jan 2022 | A1 |
20220000672 | Hunt | Jan 2022 | A1 |
20220001094 | Pratt et al. | Jan 2022 | A1 |
20220001095 | Locke et al. | Jan 2022 | A1 |
20220001096 | Locke et al. | Jan 2022 | A1 |
20220001101 | Hunt et al. | Jan 2022 | A1 |
20220001212 | Bass et al. | Jan 2022 | A1 |
20220002916 | Wheldrake | Jan 2022 | A1 |
20220008642 | Waite et al. | Jan 2022 | A1 |
20220016331 | Robinson et al. | Jan 2022 | A1 |
20220016332 | Joshi et al. | Jan 2022 | A1 |
20220023103 | Locke et al. | Jan 2022 | A1 |
20220023527 | Beadle et al. | Jan 2022 | A1 |
20220031231 | Hunt et al. | Feb 2022 | A1 |
20220031934 | Locke et al. | Feb 2022 | A1 |
20220047797 | Locke et al. | Feb 2022 | A1 |
20220062060 | Hu et al. | Mar 2022 | A1 |
20220062526 | Heaton et al. | Mar 2022 | A1 |
20220080102 | Locke et al. | Mar 2022 | A1 |
20220080103 | Locke et al. | Mar 2022 | A1 |
20220096727 | Collinson et al. | Mar 2022 | A1 |
20220117795 | Adie et al. | Apr 2022 | A1 |
20220117796 | Adie et al. | Apr 2022 | A1 |
20220117797 | Adie et al. | Apr 2022 | A1 |
20220183894 | Mumby et al. | Jun 2022 | A1 |
20220192887 | Jardret et al. | Jun 2022 | A1 |
20220193324 | Locke et al. | Jun 2022 | A1 |
20240001020 | Walton et al. | Jan 2024 | A1 |
20240009372 | Braga et al. | Jan 2024 | A1 |
20240024561 | Locke et al. | Jan 2024 | A1 |
20240058176 | Beadle et al. | Feb 2024 | A1 |
20240074907 | Eriksson et al. | Mar 2024 | A1 |
20240074909 | Rapp | Mar 2024 | A1 |
20240080969 | Askem et al. | Mar 2024 | A1 |
20240099894 | Hartwell et al. | Mar 2024 | A1 |
20240099897 | Locke et al. | Mar 2024 | A1 |
20240100238 | Gordon et al. | Mar 2024 | A1 |
20240115789 | Locke et al. | Apr 2024 | A1 |
20240115797 | Luckemeyer et al. | Apr 2024 | A1 |
20240122764 | Hunt et al. | Apr 2024 | A1 |
20240148560 | Coulthard et al. | May 2024 | A1 |
20240156645 | Braga et al. | May 2024 | A1 |
20240189492 | Gowans et al. | Jun 2024 | A1 |
20240197538 | Cole et al. | Jun 2024 | A1 |
20240207102 | Allen et al. | Jun 2024 | A1 |
Number | Date | Country |
---|---|---|
3187204 | Jul 2017 | EP |
3556407 | Oct 2019 | EP |
3569260 | Nov 2019 | EP |
3622975 | Mar 2020 | EP |
3643328 | Apr 2020 | EP |
3643330 | Apr 2020 | EP |
3643331 | Apr 2020 | EP |
3669838 | Jun 2020 | EP |
3669843 | Jun 2020 | EP |
3669844 | Jun 2020 | EP |
3827795 | Jun 2021 | EP |
3829515 | Jun 2021 | EP |
3829667 | Jun 2021 | EP |
3347068 | Jul 2021 | EP |
3441051 | Jul 2021 | EP |
3851134 | Jul 2021 | EP |
3852827 | Jul 2021 | EP |
3852829 | Jul 2021 | EP |
3606573 | Aug 2021 | EP |
3866737 | Aug 2021 | EP |
3866920 | Aug 2021 | EP |
3291849 | Sep 2021 | EP |
3880143 | Sep 2021 | EP |
3880267 | Sep 2021 | EP |
3897489 | Oct 2021 | EP |
3060181 | Nov 2021 | EP |
3434237 | Nov 2021 | EP |
3624741 | Nov 2021 | EP |
3628289 | Nov 2021 | EP |
3104816 | Dec 2021 | EP |
3322455 | Dec 2021 | EP |
3429521 | Dec 2021 | EP |
3446665 | Dec 2021 | EP |
3681452 | Dec 2021 | EP |
3932442 | Jan 2022 | EP |
3936163 | Jan 2022 | EP |
3939554 | Jan 2022 | EP |
3124062 | Feb 2022 | EP |
3687467 | Feb 2022 | EP |
3481360 | Mar 2022 | EP |
3740179 | Mar 2022 | EP |
3964185 | Mar 2022 | EP |
3454807 | Apr 2022 | EP |
3421020 | May 2022 | EP |
3871645 | May 2022 | EP |
3452132 | Jan 2024 | EP |
3592312 | Jan 2024 | EP |
3677291 | Jan 2024 | EP |
3769791 | Jan 2024 | EP |
3656408 | Feb 2024 | EP |
3659409 | Feb 2024 | EP |
3651815 | Mar 2024 | EP |
2767305 | Apr 2024 | EP |
3503857 | Apr 2024 | EP |
3703632 | Apr 2024 | EP |
3936163 | Apr 2024 | EP |
4346340 | Apr 2024 | EP |
4353271 | Apr 2024 | EP |
3292878 | May 2024 | EP |
3708197 | May 2024 | EP |
2253353 | Jun 2024 | EP |
3291849 | Jun 2024 | EP |
3470030 | Jun 2024 | EP |
3785744 | Jun 2024 | EP |
2579211 | Jun 2020 | GB |
2579368 | Jun 2020 | GB |
2589503 | Jun 2021 | GB |
2592804 | Sep 2021 | GB |
2592805 | Sep 2021 | GB |
2592806 | Sep 2021 | GB |
2005018543 | Mar 2005 | WO |
2011121394 | Oct 2011 | WO |
2011135284 | Nov 2011 | WO |
2011144888 | Nov 2011 | WO |
2013015827 | Jan 2013 | WO |
2013126049 | Aug 2013 | WO |
2014014842 | Jan 2014 | WO |
2015145117 | Oct 2015 | WO |
2015173546 | Nov 2015 | WO |
2016141450 | Sep 2016 | WO |
2017016974 | Feb 2017 | WO |
2017125250 | Jul 2017 | WO |
2018029231 | Feb 2018 | WO |
2018094061 | May 2018 | WO |
2018162613 | Sep 2018 | WO |
2018163093 | Sep 2018 | WO |
2018189265 | Oct 2018 | WO |
2018226667 | Dec 2018 | WO |
2018227144 | Dec 2018 | WO |
2018231825 | Dec 2018 | WO |
2018236648 | Dec 2018 | WO |
2019002085 | Jan 2019 | WO |
2019012068 | Jan 2019 | WO |
2019012069 | Jan 2019 | WO |
2019022493 | Jan 2019 | WO |
2019027933 | Feb 2019 | WO |
2019038548 | Feb 2019 | WO |
2019038549 | Feb 2019 | WO |
2019040656 | Feb 2019 | WO |
2019050855 | Mar 2019 | WO |
2019058373 | Mar 2019 | WO |
2019073326 | Apr 2019 | WO |
2019083563 | May 2019 | WO |
2019083868 | May 2019 | WO |
2019086911 | May 2019 | WO |
2019091150 | May 2019 | WO |
2019094147 | May 2019 | WO |
2019096828 | May 2019 | WO |
2019113275 | Jun 2019 | WO |
2019113623 | Jun 2019 | WO |
2019191590 | Oct 2019 | WO |
2019193141 | Oct 2019 | WO |
2019193333 | Oct 2019 | WO |
2019199389 | Oct 2019 | WO |
2019199596 | Oct 2019 | WO |
2019199687 | Oct 2019 | WO |
2019199798 | Oct 2019 | WO |
2019199849 | Oct 2019 | WO |
2019200035 | Oct 2019 | WO |
2019215572 | Nov 2019 | WO |
2019219613 | Nov 2019 | WO |
2019234365 | Dec 2019 | WO |
2020005062 | Jan 2020 | WO |
2020005344 | Jan 2020 | WO |
2020005536 | Jan 2020 | WO |
2020005546 | Jan 2020 | WO |
2020005577 | Jan 2020 | WO |
2020007429 | Jan 2020 | WO |
2020011691 | Jan 2020 | WO |
2020014178 | Jan 2020 | WO |
2020014310 | Jan 2020 | WO |
2020018300 | Jan 2020 | WO |
2020026061 | Feb 2020 | WO |
2020026144 | Feb 2020 | WO |
2020033351 | Feb 2020 | WO |
2020035811 | Feb 2020 | WO |
2020043665 | Mar 2020 | WO |
2020044237 | Mar 2020 | WO |
2020046443 | Mar 2020 | WO |
2020047255 | Mar 2020 | WO |
2020049038 | Mar 2020 | WO |
2020055945 | Mar 2020 | WO |
2020056014 | Mar 2020 | WO |
2020056182 | Mar 2020 | WO |
2020065531 | Apr 2020 | WO |
2020070231 | Apr 2020 | WO |
2020074512 | Apr 2020 | WO |
2020078993 | Apr 2020 | WO |
2020079009 | Apr 2020 | WO |
2020079330 | Apr 2020 | WO |
2020081259 | Apr 2020 | WO |
2020081391 | Apr 2020 | WO |
2020092598 | May 2020 | WO |
2020136555 | Jul 2020 | WO |
2020141059 | Jul 2020 | WO |
2020144347 | Jul 2020 | WO |
2020150548 | Jul 2020 | WO |
2020159675 | Aug 2020 | WO |
2020159677 | Aug 2020 | WO |
2020159678 | Aug 2020 | WO |
2020159823 | Aug 2020 | WO |
2020159859 | Aug 2020 | WO |
2020159892 | Aug 2020 | WO |
2020161086 | Aug 2020 | WO |
2020173665 | Sep 2020 | WO |
2020173760 | Sep 2020 | WO |
2020174264 | Sep 2020 | WO |
2020174510 | Sep 2020 | WO |
2020182887 | Sep 2020 | WO |
2020185810 | Sep 2020 | WO |
2020197759 | Oct 2020 | WO |
2020197760 | Oct 2020 | WO |
2020198484 | Oct 2020 | WO |
2020201879 | Oct 2020 | WO |
2020213998 | Oct 2020 | WO |
Number | Date | Country | |
---|---|---|---|
20200345903 A1 | Nov 2020 | US |